메뉴 건너뛰기




Volumn 3, Issue 6, 2012, Pages 1191-1194

Combination therapies with oxaliplatin and oral capecitabine or intravenous 5-FU show similar toxicity profiles in gastrointestinal carcinoma patients if hand-food syndrome prophylaxis is performed continuously

Author keywords

5 fluorouracil; Capecitabine; Gastrointestinal carcinoma; Hand foot syndrome

Indexed keywords

CAPECITABINE; FLUOROURACIL; FOLIC ACID; OXALIPLATIN;

EID: 84859447668     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2012.640     Document Type: Article
Times cited : (6)

References (14)
  • 1
    • 79952321958 scopus 로고    scopus 로고
    • Capecitabine and hand-foot syndrome
    • Saif MW: Capecitabine and hand-foot syndrome. Expert Opin Drug Saf 10: 159-169, 2011.
    • (2011) Expert Opin Drug Saf , vol.10 , pp. 159-169
    • Saif, M.W.1
  • 2
    • 0028078635 scopus 로고
    • Quality of life during chemotherapy in patients with symptomatic advanced colorectal cancer
    • Glimelius B, Hoffman K, Graf W, Påhlman L and Sjödén PO: Quality of life during chemotherapy in patients with symptomatic advanced colorectal cancer. Cancer 73: 556-562, 1994.
    • (1994) Cancer , vol.73 , pp. 556-562
    • Glimelius, B.1    Hoffman, K.2    Graf, W.3    Påhlman, L.4    Sjödén, P.O.5
  • 3
    • 1342290189 scopus 로고    scopus 로고
    • FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study
    • Tournigand C, Andre T, Achille E, et al: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22: 229-237, 2004.
    • (2004) J Clin Oncol , vol.22 , pp. 229-237
    • Tournigand, C.1    Andre, T.2    Achille, E.3
  • 4
    • 11144354462 scopus 로고    scopus 로고
    • Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: Integrated efficacy data and novel analyses from two large, randomized, phase III trials
    • Van Cutsem E, Hoff PM, Harper P, et al: Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomized, phase III trials. Br J Cancer 90: 1190-1197, 2004.
    • (2004) Br J Cancer , vol.90 , pp. 1190-1197
    • van Cutsem, E.1    Hoff, P.M.2    Harper, P.3
  • 5
    • 73049093340 scopus 로고    scopus 로고
    • Capecitabine plus oxaliplatin vs fluorouracil plus oxaliplatin as first line treatment for metastatic colorectal cancer - meta-analysis of six randomized trials
    • Cao Y, Liao Y, Tan A, Liu L, Mo Z and Gao F: Capecitabine plus oxaliplatin vs fluorouracil plus oxaliplatin as first line treatment for metastatic colorectal cancer - meta-analysis of six randomized trials. Colorectal Disease 12: 16-23, 2010.
    • (2010) Colorectal Disease , vol.12 , pp. 16-23
    • Cao, Y.1    Liao, Y.2    Tan, A.3    Liu, L.4    Mo, Z.5    Gao, F.6
  • 6
    • 78649873169 scopus 로고    scopus 로고
    • For the GI Group of the French Anti-Cancer Centers (FNCLCC): Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer
    • Ducreux M, Bennouna J, Hebbar M, Ychou M, Lledo G, Conroy T, Adenis A, Faroux R, Rebischung C, Bergougnoux L, Kockler L and Douillard J: For the GI Group of the French Anti-Cancer Centers (FNCLCC): Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer. Int J Cancer 128: 682-690, 2010.
    • (2010) Int J Cancer , vol.128 , pp. 682-690
    • Ducreux, M.1    Bennouna, J.2    Hebbar, M.3    Ychou, M.4    Lledo, G.5    Conroy, T.6    Adenis, A.7    Faroux, R.8    Rebischung, C.9    Bergougnoux, L.10    Kockler, L.11    Douillard, J.12
  • 7
    • 2942638081 scopus 로고    scopus 로고
    • XELOX (capecitabine plus oxaliplatin): Active first-line therapy for patients with metastatic colorectal cancer
    • Cassidy J, Tabernero J, Twelves C, et al: XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol 22: 2084-2091, 2004.
    • (2004) J Clin Oncol , vol.22 , pp. 2084-2091
    • Cassidy, J.1    Tabernero, J.2    Twelves, C.3
  • 8
    • 33646142547 scopus 로고    scopus 로고
    • Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: The X-ACT trial
    • Cassidy J, Douillard JY, Twelves C, et al: Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trial. Br J Cancer 94: 1122-1129, 2006.
    • (2006) Br J Cancer , vol.94 , pp. 1122-1129
    • Cassidy, J.1    Douillard, J.Y.2    Twelves, C.3
  • 10
    • 42949150908 scopus 로고    scopus 로고
    • Randomized phase III study of capecitabine plus oxaliplatin as first-line therapy for metastatic colorectal cancer
    • Cassidy J, Clarke S, Diaz-Rubio E, et al: Randomized phase III study of capecitabine plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol 26: 2006-2012, 2008.
    • (2008) J Clin Oncol , vol.26 , pp. 2006-2012
    • Cassidy, J.1    Clarke, S.2    Diaz-Rubio, E.3
  • 11
    • 0035503151 scopus 로고    scopus 로고
    • Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: Results of a large phase III study
    • Van Cutsem E, Twelves C, Cassidy J, et al: Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 19: 4097-4106, 2001.
    • (2001) J Clin Oncol , vol.19 , pp. 4097-4106
    • van Cutsem, E.1    Twelves, C.2    Cassidy, J.3
  • 12
    • 53049092394 scopus 로고    scopus 로고
    • Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: A randomized phase III noninferiority study
    • Rothenberg ML, Cox JV, Butts C, Navarro M, Bang YJ, Goel R, Gollins S, Siu LL, Laguerre S and Cunningham D: Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study. Annals of Oncology 19: 1720-1726, 2008.
    • (2008) Annals of Oncology , vol.19 , pp. 1720-1726
    • Rothenberg, M.L.1    Cox, J.V.2    Butts, C.3    Navarro, M.4    Bang, Y.J.5    Goel, R.6    Gollins, S.7    Siu, L.L.8    Laguerre, S.9    Cunningham, D.10
  • 13
    • 0035871538 scopus 로고    scopus 로고
    • Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: Results of a randomized phase III study
    • Hoff PM, Ansari R, Batist G, et al: Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 19: 2282-2292, 2001.
    • (2001) J Clin Oncol , vol.19 , pp. 2282-2292
    • Hoff, P.M.1    Ansari, R.2    Batist, G.3
  • 14
    • 84859465648 scopus 로고    scopus 로고
    • Capecitabine versus 5-fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: Final results from the X-ACT trial with analysis by age and preliminary evidence of a pharmacodynamic marker of efficacy
    • Sep 6, (Epub ahead of print)
    • Twelves C, Scheithauer W, McKendrick J, Seitz JF, Van Hazel G, Wong A, Díaz-Rubio E, Gilberg F and Cassidy J: Capecitabine versus 5-fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results from the X-ACT trial with analysis by age and preliminary evidence of a pharmacodynamic marker of efficacy. Ann Oncol Sep 6, 2011 (Epub ahead of print).
    • (2011) Ann Oncol
    • Twelves, C.1    Scheithauer, W.2    McKendrick, J.3    Seitz, J.F.4    van Hazel, G.5    Wong, A.6    Díaz-Rubio, E.7    Gilberg, F.8    Cassidy, J.9


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.